Screener
Acadia Pharmaceuticals ACAD Gain Loss On Disposition Of Intangible Assets
Gain Loss On Disposition Of Intangible Assets at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfIntangibleAssets.
The source filing: Acadia Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 25, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-072519
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Cost of product sales | 88,998 | 81,841 | 41,638 |
| Research and development | 328,802 | 303,249 | 351,619 |
| Selling, general and administrative | 548,894 | 488,428 | 406,559 |
| Gain on sale of non-financial asset | — | (146,515) | — |
| Total operating expenses | 966,694 | 727,003 | 799,816 |
| Income (loss) from operations | 104,811 | 230,794 | (73,379) |
| Interest income, net | 31,722 | 25,458 | 17,234 |
| Other income | 2,371 | 1,823 | 5,109 |
Item 16. Form 10-K Summary
FAQ
- What is Acadia Pharmaceuticals's gain loss on disposition of intangible assets?
- Acadia Pharmaceuticals (ACAD) reported gain loss on disposition of intangible assets of $0 in Q4 2025.
- How has Acadia Pharmaceuticals's gain loss on disposition of intangible assets changed year-over-year?
- Acadia Pharmaceuticals's gain loss on disposition of intangible assets decreased by 100.0% year-over-year, from $36.63M to $0.
- What does gain loss on disposition of intangible assets mean?
- Gain Loss On Disposition Of Intangible Assets as reported by Acadia Pharmaceuticals Inc..
Ask your AI about Acadia Pharmaceuticals's gain loss on disposition of intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude